MedTrace Logo

An Efficacy and Safety Evaluation of Nasacort AQ in Children Ages 2-5 Years With Perennial Allergic Rhinitis

NCT00132925 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 460

Last updated 2011-01-11

No results posted yet for this study

Summary

The purposes of this study are:

* To demonstrate the efficacy of once daily administration of Nasacort AQ 110 µg compared with placebo in children 2-5 years of age with perennial allergic rhinitis; and
* To assess the safety of Nasacort AQ 110 µg in children 2-5 years of age.

Conditions

  • Rhinitis, Allergic, Perennial

Interventions

DRUG

Triamcinolone

Sponsors & Collaborators

Principal Investigators

  • Phyllis Diener, BS, MT (ASCP) · Sanofi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
5 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-11-30
Completion
2006-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00132925 on ClinicalTrials.gov